drugset / Trial / NCT02937350
Clearance of 25-hydroxyvitamin D in Chronic Kidney Disease
Phase 1
Completed
88 enrolled
University of Washington
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · collab
NaSingle-groupOpen-labelDiagnostic
Summary
The goal of this study is to better understand vitamin D catabolism and how it is affected by CKD and race.
Timeline
- Start
- 2017-03-01
- Primary completion
- 2019-07-08
- Completion
- 2021-01-01
Publications
- Best CM, Thummel KE, Hsu S, Lin Y, Zelnick LR, Kestenbaum B, Kushnir MM, de Boer IH, Hoofnagle AN. The plasma free fraction of 25-hydroxyvitamin D3 is not strongly associated with 25-hydroxyvitamin D3 clearance in kidney disease patients and controls. J Steroid Biochem Mol Biol. 2023 Feb;226:106206. doi: 10.1016/j.jsbmb.2022.106206. Epub 2022 Oct 28.
- Hsu S, Zelnick LR, Lin YS, Best CM, Kestenbaum B, Thummel KE, Rose LM, Hoofnagle AN, de Boer IH. Differences in 25-Hydroxyvitamin D Clearance by eGFR and Race: A Pharmacokinetic Study. J Am Soc Nephrol. 2021 Jan;32(1):188-198. doi: 10.1681/ASN.2020050625. Epub 2020 Oct 28.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | D6-25-hydroxyvitamin D3 | Unknown | — | Intravenous |